Dysbiosis and colonization with Staphylococcus aureus is considered to play an important role in the pathogenesis of atopic dermatitis (AD). Recovering this dysbiosis may improve AD symptoms. Omiganan is a synthetic indolicidin analogue antimicrobial peptide with activity against S. aureus and could be a viable new treatment option for AD.
Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial.
CHDR
van der Kolk TN, Buters TP, Krouwels L, Boltjes J, de Kam ML, van der Wall H, van Alewijk DCJG, van den Munckhof EHA, Becker MJ, Feiss G, Florencia EF, Prens EP, Moerland M, Burggraaf J, Rissmann R, van Doorn MBA
